Quinagolide
- Atc Codes:G02CB04
- CAS Codes:87056-78-8#94424-50-7
- PHARMGKB ID:87056-78-8#94424-50-7
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Norprolac; Belgium: Norprolac; Cyprus: Norprolac; Czech Republic: Norprolac; Denmark: Norprolac; Finland: Norprolac; France: Norprolac; Germany: Norprolac; Greece: Norprolac; Hungary: Norprolac; Ireland: Norprolac; Luxembourg: Norprolac; Netherlands: Norprolac; Poland: Norprolac; Portugal: Norprolac; Slovakia: Norprolac; Slovenia: Norprolac; Spain: Norprolac; Sweden: Norprolac; UK: Norprolac.
North America
Canada: Norprolac.
Latin America
Mexico: Norprolac.
Drug combinations
Chemistry
Quinagolide: C~20~H~33~N~3~O~3~S. Mw: 395.56. (±)-N,N-Diethyl-N’-[(3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo[g]quinolin-3-yl]sulfamide. CAS-87056-78-8; CAS-94424-50-7 (hydrochloride).
Pharmacologic Category
Hormones and Synthetic Substitutes; Pituitary. Anti-hyperprolactinemic Agent, Dopamine (D~2~) Agonist. (ATC-Code: G02CB04).
Mechanism of action
Selective dopamine D~2~ receptor agonist. Inhibits lactotroph cells in anterior pituitary gland which synthesize and secrete prolactin.
Therapeutic use
Hyperprolactinemia.
Pregnancy and lactiation implications
No embryotoxic or teratogenic effects in animals. Discontinue use with confirmed pregnancy unless continuation medically necessary. Not recommended in nursing women (by inhibiting prolactin secretion, quinagolide suppresses lactation).
Unlabeled use
Contraindications
Hypersensitivity to quinagolide or any component of the formulation. Hepatic/renal impairment.
Warnings and precautions
Use with caution in women of childbearing age. Use caution when discontinuing therapy in patients who become pregnant. Use may be associated with frequent (but transient) nausea and vomiting early in therapy. Hypotensive episodes with syncope may occur with onset of therapy. Risk of sudden sleep onset and somnolence (especially in Parkinson’s disease). Use with caution in prior psychotic disorders.